Switzerland’s Obseva eyes China re-start for fertility drug that failed trial | Reuters

ObsEva struck a pact with China’s Yuyuan BioScience Technology to develop and commercialize the fertility drug nolasiban, the Swiss drugmaker said on Monday as it seeks to inject new life into a medicine that had flopped a trial.

@ Reuters | January 13, 2020

135 thoughts on “Switzerland’s Obseva eyes China re-start for fertility drug that failed trial | Reuters”

Leave a Reply

Your email address will not be published. Required fields are marked *